About EUSA | People | Portfolio | Partners & Investors | News | Site Map | Contact

Products

Caphosol®

CAPHOSOL®, a topical oral agent, is a U.S. patented, prescription medical device that lubricates the mucosa and helps maintain the integrity of the oral cavity through its mineralizing potential. The distinguishing feature of CAPHOSOL® is its high concentrations of calcium and phosphate ions, which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the epithelium and permeating the mucosal lesion in mucositis. Calcium ions play a crucial role in several aspects of the inflammatory process, the blood clotting cascade, and tissue repair and phosphate ions may be a valuable supplemental source of phosphates for damaged mucosal surfaces.

CAPHOSOL® is indicated in the U.S. as an adjunct to standard oral care in treating oral mucositis caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with an amelioration of pain.

CAPHOSOL® is also indicated for dryness of the mouth (hyposalivation) or throat (xerostomia) regardless of the cause or whether the conditions are temporary or permanent. CAPHOSOL® is an unclassified medical device and is marketed under a 510(k) Premarket Notification Application.

For further information on CAPHOSOL® visit www.caphosol.com. For information on our products, where they are available and prescribing information, please see the Product Summary table

Download pdf
PI: Download PDF

 

CAPHOSOL®

 

Portfolio
Caphosol®
Collatamp®
Erwinase®
Fomepizole
Kidrolase®
ProstaScint®
Quadramet®
Rapydan®
Xenazine®

Product Summary

Pipeline

Business Development
Opportunities

 

 
Back to home page Legal | Privacy Policy
Registered in England 4555273 Registered Office The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA Vat Registration No: 896 1192 88
©Eusa Pharma (Europe) Ltd. All rights reserved.